Primary targets of fluoroquinolones in Streptococcus pneumoniae

被引：144

作者：

Fukuda, H

Hiramatsu, K

机构：

[1] Kyorin Pharmaceut Co Ltd, Cent Res Labs, Shimotsuga, Tochigi 3290114, Japan

[2] Juntendo Univ, Dept Bacteriol, Bunkyo Ku, Tokyo 1138421, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1999年 / 43卷 / 02期

关键词：

D O I：

10.1128/AAC.43.2.410

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Mutants of wild-type Streptococcus pneumoniae IID553 with mutations in parC were obtained by selection with trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin. All of the parC mutants were cross-resistant to the selecting agents but were not resistant to gatifloxacin and sparfloxacin. On the other hand, gyrA mutants were isolated by selection with gatifloxacin and sparfloxacin. The gyrA mutants were cross-resistant to gatifloxacin and sparfloxacin but were not resistant to the other fluoroquinolones tested. These results suggest that in wild-type S. pneumoniae the primary target of trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin is topoisomerase IV, whereas the primary target of gatifloxacin and sparfloxacin is DNA gyrase.

引用

收藏

页码：410 / 412

页数：3

相关论文

共 21 条

[1] Molecular characterization of the gene encoding the DNA gyrase a subunit of Streptococcus pneumoniae [J].

Balas, D ;

Fernández-Moreira, E ;

De la Campa, AG .

JOURNAL OF BACTERIOLOGY, 1998, 180 (11) :2854-2861

[2] Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae [J].

Baranova, NN ;

Neyfakh, AA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1396-1398

[3] CHEMI-LUMINESCENT DETECTION OF DNA - APPLICATION FOR DNA SEQUENCING AND HYBRIDIZATION [J].

BECK, S ;

OKEEFFE, T ;

COULL, JM ;

KOSTER, H .

NUCLEIC ACIDS RESEARCH, 1989, 17 (13) :5115-5123

[4] Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases [J].

Blanche, F ;

Cameron, B ;

Bernard, FX ;

Maton, L ;

Manse, B ;

Ferrero, L ;

Ratet, N ;

Lecoq, C ;

Goniot, A ;

Bisch, D ;

Crouzet, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2714-2720

[5] CLONING AND PRIMARY STRUCTURE OF STAPHYLOCOCCUS-AUREUS DNA TOPOISOMERASE-IV - A PRIMARY TARGET OF FLUOROQUINOLONES [J].

FERRERO, L ;

CAMERON, B ;

MANSE, B ;

LAGNEAUX, D ;

CROUZET, J ;

FAMECHON, A ;

BLANCHE, F .

MOLECULAR MICROBIOLOGY, 1994, 13 (04) :641-653

[6] ANALYSIS OF GYRA AND GRLA MUTATIONS IN STEPWISE-SELECTED CIPROFLOXACIN-RESISTANT MUTANTS OF STAPHYLOCOCCUS-AUREUS [J].

FERRERO, L ;

CAMERON, B ;

CROUZET, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1554-1558

[7] Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus [J].

Fukuda, H ;

Hori, S ;

Hiramatsu, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :1917-1922

[8] Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro [J].

Gootz, TD ;

Zaniewski, R ;

Haskell, S ;

Schmieder, B ;

Tankovic, J ;

Girard, D ;

Courvalin, P ;

Polzer, RJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2691-2697

[9] INVITRO AND INVIVO ANTIBACTERIAL ACTIVITIES OF AM-1155, A NEW 6-FLUORO-8-METHOXY QUINOLONE [J].

HOSAKA, M ;

YASUE, T ;

FUKUDA, H ;

TOMIZAWA, H ;

AOYAMA, H ;

HIRAI, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (10) :2108-2117

[10] ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype [J].

Munoz, R ;

DelaCampa, AG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2252-2257